The 2nd preprint from G2P-Japan is out at @biorxivpreprint !
We revealed that the SARS-CoV-2 delta variant (B.1.617.2 lineage) is highly fusogenic and #P681R mutation, a hallmark in the B.1.617 lineage, is its determinant. Please retweet 1/3…
In this study, we demonstrated that #P681R mutation in the SARS-CoV-2 spike protein enhances and further accelerates SARS-CoV-2 spike-mediated cell-cell fusion. 2/3
Photo: Syncytia formed by SARS-CoV-2 infection in VeroE6/TMPRSS2 cells. Note that B.1.617.2 is the delta variant, and B.1.617.1 is a variant emerged in India. B.1.1 is a prototype. Referred from Figure 2B of our preprint. 3/3

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with The Sato Lab (Kei Sato)

The Sato Lab (Kei Sato) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @SystemsVirology

18 Jun
当研究室が主宰する新型コロナ研究コンソーシアム「G2P-Japan」のプレプリント第2弾を、@biorxivpreprint に発表しました。
本研究ではまず、 #デルタ株 (通称 #インド株 、B.1.617.2系統)に感染した細胞が、周囲の細胞と「くっつきやすい」ことを明らかにしました。 1/4…
そしてその「くっつきやすさ」が、 #P681R 変異という、デルタ株特有のスパイクタンパク質の変異によって引き起こされることを明らかにしました。 2/4
↓は、プレプリントからの抜粋・改変した、新型コロナに感染した細胞の写真。従来株(B.1.1系統)に比べて、 #インド株 (B.1.617.1とB.1.617.2系統)に感染した細胞は周囲の細胞と「くっつきやすく」、より大きな細胞塊を形成します(G2P-Japanメンバー、清水健太博士@北海道大学が撮影・提供)。 3/4
Read 4 tweets
5 Apr
#拡散希望 当ラボが主催する新型コロナ研究コンソーシアム「The G2P-Japan」の研究成果をbioRxiv @biorxivpreprint に掲載しました。
概要:流行拡大する #新型コロナ の変異株のひとつ #カリフォルニア株 が、日本人の免疫から逃避する可能性を明らかにしました。1/11…
ヒトの免疫、特に #獲得免疫 は、#液性免疫(中和抗体)」と #細胞性免疫 に大別されます。イギリス株やブラジル株などの新型コロナ変異株が、液性免疫(中和抗体)から逃避する可能性については世界中で研究が進んでいますが、細胞性免疫からの逃避の可能性については報告がありませんでした。2/11
The G2P-Japanでは、まず、新型コロナウイルスのスパイクタンパク質の一部が、「HLA-A24」という、日本人に多く見られる型の細胞性免疫によってきわめて強く認識される(つまり、HLA-A24のエピトープになる)ことを、免疫学実験によって実証しました。3/11
Read 11 tweets
5 Apr
A new preprint "An emerging SARS-CoV-2 mutant (='the California variant', B.1.427/429) evading cellular immunity and increasing viral infectivity", from The G2P-Japan consortium, organized by my lab, is out at @biorxivpreprint. Please RT 1/7…
During the current SARS-CoV-2 pandemic that is devastating the modern societies worldwide, many variants that naturally acquire multiple mutations have emerged. Emerging mutations can affect viral properties such as infectivity and immune resistance. 2/7
The sensitivity of naturally occurring SARS-CoV-2 variants to 'humoral immunity (=neutralizing antibodies)' has recently been investigated. However, the impact of viral mutations to human leukocyte antigen (HLA)-restricted 'cellular immunity' remains unaddressed. 3/7
Read 9 tweets
12 May 20
Please notice: we revealed that SARS-CoV-2 ORF3b, one of the most different genes compared to SARS-CoV, strongly hampers human type I IFN activation. Its inhibitory activity is stronger than the SARS-CoV ortholog and influenza A virus NS1. #COVID19 1/7…
Our findings may explain the poor IFN responses in #COVID19 patients and SARS-CoV-2-infected cells compared to SARS-CoV- and influenza A virus-infected cells, recently reported by @DBM003 @virusninja and so on, are attributed to the remarkable ability of SARS-CoV-2 ORF3b. 2/7
Additionally, we revealed that the ORF3b genes of SARS-CoV-2-related viruses in bats and pangolins are very similar to that of SARS-CoV-2 and possess the activity to inhibit IFN activation. 3/7
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!